CriticalProkinetic, peripheral dopamine D2 receptor antagonist×Fourth-generation fluoroquinolone
Updated · Methodology
Mechanism
Moxifloxacin prolongs the heart-rate-corrected QT interval (QTc) on the electrocardiogram in some patients, and the prolongation may increase as the drug's blood level rises (moxifloxacin summaries of product characteristics, SmPCs, Spanish Agency of Medicines and Medical Devices, AEMPS, and moxifloxacin label, US Food and Drug Administration, FDA). The Spanish moxifloxacin SmPC does not rule out an additive effect on the QT interval with other QTc-prolonging drugs, which may increase the risk of ventricular arrhythmias, including torsade de pointes (AEMPS). Domperidone is associated with QT prolongation. Epidemiological studies also link it to a higher risk of serious ventricular arrhythmias and sudden cardiac death, especially in people over 60, at doses above 30 mg a day, and with QT-prolonging drugs or inhibitors of the enzyme CYP3A4 (domperidone SmPC, AEMPS). The Spanish domperidone SmPC attributes the contraindication of such combinations to a higher risk of QT prolongation from pharmacodynamic or pharmacokinetic interactions and lists moxifloxacin among the contraindicated antibiotics (AEMPS). Moxifloxacin is unlikely to interact with other drugs through cytochrome P450 enzymes (moxifloxacin SmPC, AEMPS), and the documents say nothing about its effect on domperidone levels.
Symptoms
QT prolongation itself causes no symptoms and shows only on an electrocardiogram (ECG), while an arrhythmia causes palpitations, dizziness and fainting. With moxifloxacin, QT prolongation (common in people with low potassium), palpitations, fast heart rate, atrial fibrillation and angina are uncommon, ventricular tachyarrhythmias and fainting are rare, and torsade de pointes and cardiac arrest are very rare (moxifloxacin summary of product characteristics, SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). With domperidone, QT prolongation and torsade de pointes have been reported very rarely, and these reports included people with other risk factors, electrolyte disturbances or concomitant medicines (domperidone SmPC, AEMPS). The risk of arrhythmia is higher with low or high potassium, low magnesium or a slow heart rate (domperidone SmPC, AEMPS), and women and older people may be more sensitive to QT-prolonging drugs (moxifloxacin SmPC, AEMPS).
Management
The combination is contraindicated. The Spanish domperidone summary of product characteristics (SmPC) contraindicates domperidone with QT-prolonging drugs and names moxifloxacin among these antibiotics (domperidone SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). The moxifloxacin documents contraindicate the combination too. The contraindications section of the Spanish moxifloxacin SmPCs says not to give moxifloxacin together with other QT-prolonging drugs, and the domperidone SmPC itself describes QT prolongation with domperidone (moxifloxacin and domperidone SmPCs, AEMPS). The US moxifloxacin label says to avoid moxifloxacin with other QT-prolonging drugs (moxifloxacin label, US Food and Drug Administration, FDA). Moxifloxacin is also contraindicated in QT prolongation, electrolyte disturbances, especially uncorrected low potassium, clinically relevant bradycardia, heart failure with reduced ejection fraction and a history of symptomatic arrhythmias (moxifloxacin SmPCs, AEMPS), and domperidone in known QT prolongation, significant electrolyte disturbances, bradycardia and heart disease such as congestive heart failure (AEMPS). Do not exceed the recommended moxifloxacin dose, and infuse the intravenous dose of 400 mg once a day over at least 60 minutes (moxifloxacin SmPCs, AEMPS). Use domperidone at the lowest effective dose, no more than 30 mg a day in adults, and usually for no longer than one week (domperidone SmPC, AEMPS). If signs of arrhythmia appear, stop moxifloxacin and record an electrocardiogram (ECG), and stop domperidone as well (moxifloxacin and domperidone SmPCs, AEMPS).
Your whole list in one report
Up to 15 drugs: every pair in one table and a PDF report. Your first report is free: we only ask for your email
Add more drugsMedicine list: everything you take in one place →
Sources
- FDA: Moxifloxacin tablets (Chartwell RX) – prescribing information (2026)– FDA label, Chartwell RX, DailyMed setid 656f582c-ecba-4ec8-9420-9562114d889b, version 1, 08/2026, sections 5.6 (QT Prolongation) and 7.5 (Drugs that Prolong QT)
- AEMPS: Ficha técnica: Moxifloxacino (nº registro 74573), sección 4.5 (2026)– AEMPS, CIMA, nº registro 74573, revisión 03/2026, sección 4.5
- AEMPS: Ficha técnica: Domperidona (nº registro 55411), sección 4.3 (2025)– AEMPS, CIMA, nº registro 55411 (Motilium 1 mg/ml suspensión oral, Esteve), revisión 09/2025, secciones 4.2, 4.3, 4.4 y 4.5
- AEMPS: Ficha técnica: Moxifloxacino, Actira 400 mg/250 ml solución para perfusión (nº registro 83222), sección 4.3 (2026)– AEMPS, CIMA, nº registro 83222 (Actira 400 mg/250 ml solución para perfusión, Bayer Hispania), revisión 02/2026, secciones 4.3, 4.4, 4.5 y 4.8